Case Report: Severe Hepatitis With Sotorasib After Immunotherapy Case Report: Severe Hepatitis With Sotorasib After Immunotherapy
A case report of life-threatening hepatitis in a lung cancer patient suggests caution when using second-line sotorasib in patients previously treated with checkpoint inhibitors.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - October 14, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Researchers Open Phase I Clinical Trial of Cryoablation with Keytruda
Memorial Sloan Kettering Cancer Center in New York City has opened a novel clinical trial that combines the immunotherapy drug Keytruda with cryoablation for patients with unresectable malignant mesothelioma. The phase I trial opened in September and will be available at seven Memorial Sloan Kettering locations in the New York City/New Jersey area. Cryoablation, which is also known as cryotherapy or cryosurgery, is a treatment that freezes localized tumors with argon gas or liquid nitrogen. It has been used effectively with liver, kidney and prostate cancers, but its use with mesothelioma has been limited because of ...
Source: Asbestos and Mesothelioma News - October 14, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

Could Your Patient Benefit? New Trials in Lung Cancer Could Your Patient Benefit? New Trials in Lung Cancer
Trials of new drugs for lung cancer have begun enrollment in recent months, including several testing investigational new immunotherapies. Could one of your patients could benefit from being enrolled?Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - October 14, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

New treatment destroys head and neck cancer tumours in trial
Exclusive: combination of drugs causes tumours to vanish in some terminally ill patients, study findsA new cancer treatment can wipe out tumours in terminally ill head and neck cancer patients, scientists have discovered.In a landmark trial, a cocktail of immunotherapy medications harnessed patients ’ immune systems to kill their own cancer cells and prompted “a positive trend in survival”, according to researchers at the Institute of Cancer Research (ICR), London, and the Royal Marsden NHS foundation trust.Continue reading... (Source: Guardian Unlimited Science)
Source: Guardian Unlimited Science - October 11, 2021 Category: Science Authors: Andrew Gregory Health editor Tags: Cancer Medical research Health Science NHS UK news Source Type: news

New cancer treatment destroys tumours in terminally ill, finds trial
Exclusive: combining immunotherapy drugs may prove effective treatment with fewer side-effects than chemotherapyA new cancer treatment can wipe out tumours in terminally ill patients, scientists have discovered.In a landmark trial, a cocktail of immunotherapy medications harnessed patients ’ immune systems to kill their own cancer cells and prompted “a positive trend in survival”, according to researchers at the Institute of Cancer Research (ICR), London, and the Royal Marsden NHS foundation trust.One patient, who was expected to die four years ago, told the Guardian of the “amazing” moment nu...
Source: Guardian Unlimited Science - October 11, 2021 Category: Science Authors: Andrew Gregory Health editor Tags: Cancer Medical research Health Science NHS UK news Source Type: news

Nanobiotix highlights ASTRO research studies
Nanobiotix will present results from clinical trials of its NBTXR3 radioenhance...Read more on AuntMinnie.comRelated Reading: ASTRO to require masks at October annual meeting PET/CT shows promise predicting outcomes in head, neck cancer ASTRO commits to October in-person annual meeting in Chicago RT + immunotherapy = head/neck cancer treatment option Nanobiotix plans head and neck cancer treatment trial (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - October 7, 2021 Category: Radiology Source Type: news

New Opdivo/Yervoy Mesothelioma Clinical Trial Begins Soon
A novel clinical trial involving the immunotherapy combination of Opdivo and Yervoy will open soon in Chicago. The goal is to study the drugs’ efficacy when added to surgery for patients with peritoneal mesothelioma cancer. The single-center, phase II clinical trial follows a recent report detailing the impressive three-year effectiveness of the drug combination when used for unresectable pleural mesothelioma. Bristol Myers Squibb manufactures Opdivo and Yervoy, known generically as nivolumab and ipilimumab. The U.S. Food and Drug Administration approved the combination for pleural mesothelioma in 2020, making ...
Source: Asbestos and Mesothelioma News - October 7, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

Virtual Symposium to Focus on Mesothelioma Treatment Advances
Sylvester Comprehensive Cancer Center of South Florida will host its free virtual First Miami International Mesothelioma Symposium on November 6, 2021. The Mesothelioma Program at the Sylvester Comprehensive Cancer Center has grown to become one of America’s leaders in this specialized field, attracting a wide range of expertise for its upcoming virtual symposium. “Mesothelioma is such a rare disease that we really have to bring in experts from around the world to get a true picture of what’s coming next. And I think we’ve done that with our program,” medical oncologist Dr. Estelamari Ro...
Source: Asbestos and Mesothelioma News - October 5, 2021 Category: Environmental Health Authors: Amy Edel Source Type: news

Improving Therapeutic Success: Focus on Cell and Gene Therapy
Researchers combine immune profiling with single cell sequencing to enhance immunotherapies. (Source: The Scientist)
Source: The Scientist - October 1, 2021 Category: Science Tags: The Marketplace Source Type: news

Many Patients, Doctors Unaware of Advancements in Cancer Care
New survey results suggest that doctors in fields other than cancer don’t know about recent advances, particularly in immunotherapy. (Source: WebMD Health)
Source: WebMD Health - September 29, 2021 Category: Consumer Health News Source Type: news

Study Shows Access to Care Often Difficult for Mesothelioma Patients
When it comes to malignant pleural mesothelioma, not everyone is treated equally. A disparity in access to care makes the difference in mesothelioma treatment quite dramatic, according to the University of Miami’s Sylvester Comprehensive Cancer Center. “Patients without access to expert multidisciplinary care at high-volume, academic facilities are being inappropriately undertreated for their disease,” medical oncologist Dr. Estelamari Rodriguez told The Mesothelioma Center at Asbestos.com. “The access is not adequate as it should be for everyone.” Rodriguez led a recent study at Univers...
Source: Asbestos and Mesothelioma News - September 28, 2021 Category: Environmental Health Authors: Chris Elkins Source Type: news

Cancer Without Chemotherapy: ‘A Totally Different World’
A growing number of cancer patients, especially those with breast and lung cancers, are being spared the dreaded treatment in favor of other options. (Source: NYT Health)
Source: NYT Health - September 27, 2021 Category: Consumer Health News Authors: Gina Kolata Tags: Chemotherapy Breast Cancer Lung Cancer Genetics and Heredity Drugs (Pharmaceuticals) Women and Girls Tumors Immunotherapy Longevity Source Type: news

Therapy using dual immune system cells effectively controls neuroblastoma
A newly developed immunotherapy that simultaneously uses modified immune-fighting cells to home in on and attack two antigens, or foreign substances, on cancer cells was highly effective in mice implanted with human neuroblastoma tissue, report researchers from the UNC Lineberger Comprehensive Cancer Center and the UNC School of Medicine. (Source: World Pharma News)
Source: World Pharma News - September 23, 2021 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Acquisition expands research in cancer immunology
Boehringer Ingelheim Acquires Abexxa Biologics to Further Expand its Research Efforts in Cancer Immunology and Novel Immunotherapeutic Approaches  Boehringer Ingelheim aims to develop novel cancer therapies by leveraging Abexxa ’s unique technology and breakthrough antibody-based drugs.   Abexxa ’s focus is on the development of specific antibodies to intracellular antigens presented by the non-classical MHC Class I molecule, HLA-E (human leucocyte antigens), enabling the development of cancer immunotherapies potentially benefiting a broader range of patients and cancer types.The addition of Abex...
Source: Boehringer Ingelheim Corporate News - September 21, 2021 Category: Research Source Type: news

New Data on RYBREVANT ® (amivantamab-vmjw) in Combination with Lazertinib Show Early Activity in Patients with Non-Small Cell Lung Cancer Whose Disease Has Progressed After Both Osimertinib and Platinum-Based Chemotherapy
September 19, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced preliminary results from the Phase 1b CHRYSALIS-2 (NCT04077463) study evaluating RYBREVANT® (amivantamab-vmjw) in combination with lazertinib in the treatment of patients with non-small cell lung cancer (NSCLC) characterized by epidermal growth factor receptor (EGFR) exon 19 deletion or L858R mutations whose disease had progressed after treatment with osimertinib and platinum chemotherapy.[i] While previously reported results have demonstrated durable responses with RYBREVANT® in combination with...
Source: Johnson and Johnson - September 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

RYBREVANT ® (amivantamab-vmjw) Provides Higher Activity and Longer Duration of Response When Used in Combination with Lazertinib in Patients with Advanced EGFR-Mutant Non-Small Cell Lung Cancer Who Have Failed Osimertinib
September 19, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced a new analysis from the CHRYSALIS (NCT02609776) study evaluating RYBREVANT® (amivantamab-vmjw) monotherapy and a combination regimen with lazertinib in advanced non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations who progressed after osimertinib.[1] The analysis showed higher activity and longer duration of response (DOR) in patients treated with the combination therapy, demonstrating the potential benefit of targeting the extracellular (outer) and catal...
Source: Johnson and Johnson - September 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Bay Area biotechs soar on coattails of AstraZeneca cancer drug study
Shares of a Bay Area biotech company shot up more than 157% and another climbed to a lesser degree Friday after a Big Pharma company reported that a cancer drug with a shared target appeared effective in fighting tumors. Both Corvus Pharmaceuticals Inc. (Nasdaq: CRVS) of Burlingame and Arcus Biosciences Inc. (NYSE: RCUS) of Hayward shot up after AstraZeneca plc reported fresh data from a mid-stage clinical trial. That Big Pharma player said its already-approved cancer immunotherapy Imfinzi showed… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - September 17, 2021 Category: Pharmaceuticals Authors: Ron Leuty Source Type: news

Bay Area biotechs soar on coattails of AstraZeneca cancer drug study
Shares of a Bay Area biotech company shot up more than 157% and another climbed to a lesser degree Friday after a Big Pharma company reported that a cancer drug with a shared target appeared effective in fighting tumors. Both Corvus Pharmaceuticals Inc. (Nasdaq: CRVS) of Burlingame and Arcus Biosciences Inc. (NYSE: RCUS) of Hayward shot up after AstraZeneca plc reported fresh data from a mid-stage clinical trial. That Big Pharma player said its already-approved cancer immunotherapy Imfinzi showed… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - September 17, 2021 Category: Biotechnology Authors: Ron Leuty Source Type: news

Flurry of Cancer Drug Endorsements From EU Panel Flurry of Cancer Drug Endorsements From EU Panel
The European Medicines Agency panel recommended for approval three new cancer drugs and additional indications for two other already marketed immunotherapies.International Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 17, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

' Urgent' Need to Understand Immunotherapy De-escalation in NSCLC'Urgent' Need to Understand Immunotherapy De-escalation in NSCLC
The strong and durable response to immunotherapy in some patients suggests treatment could be reduced or withdrawn, but questions surround which patients will be ideal candidates, an expert argues.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 17, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Janssen Presents Results from Phase 1b/2 NORSE Study in Patients with Metastatic or Locally Advanced Urothelial Carcinoma Treated with BALVERSA ® (erdafitinib) in Combination with Cetrelimab, a PD-1 Inhibitor
September 17, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results from the Phase 1b/2 NORSE (NCT03473743) study evaluating BALVERSA® (erdafitinib) in combination with cetrelimab, an anti-programmed cell death protein 1 (PD-1) monoclonal antibody, compared to BALVERSA® monotherapy in patients with locally advanced or metastatic urothelial carcinoma (mUC) with fibroblast growth factor receptor (FGFR)3 or FGFR2 genetic alterations who are ineligible for cisplatin, a current standard of care treatment for mUC. The results were highlighted in an oral present...
Source: Johnson and Johnson - September 17, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Texas allergy company partners with Valley practice to make Arizona debut
Phoenix-based Allergy Associates and Asthma Ltd. (AAA), which has multiple locations in the Valley, has teamed up with a national company to bring new treatments to its patients. The partnership will be the Arizona debut for Aspire Allergy& Sinus, which is based in Austin, Texas, and now has nearly 60 clinics in five states. The company is known for developing treatments such as allergy drops, ExACT Immunoplasty for environmental, household, and seasonal allergies, and oral immunotherapy for food … (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - September 16, 2021 Category: Pharmaceuticals Authors: Jeff Gifford Source Type: news

Texas allergy company partners with Valley practice to make Arizona debut
Phoenix-based Allergy Associates and Asthma Ltd. (AAA), which has multiple locations in the Valley, has teamed up with a national company to bring new treatments to its patients. The partnership will be the Arizona debut for Aspire Allergy& Sinus, which is based in Austin, Texas, and now has nearly 60 clinics in five states. The company is known for developing treatments such as allergy drops, ExACT Immunoplasty for environmental, household, and seasonal allergies, and oral immunotherapy for food … (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - September 16, 2021 Category: Biotechnology Authors: Jeff Gifford Source Type: news

Immunotherapy for Cancer Patients With Poor PS Needs a Rethink Immunotherapy for Cancer Patients With Poor PS Needs a Rethink
Use of check point inhibitors for patients with advanced cancer who have poor performance status (PS) needs a rethink, says editorialists.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 16, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Mesothelioma Research, COVID Findings Featured at IASLC Conference
This study, performed during the pre-vaccine period of the pandemic, once again demonstrates the importance of vaccination against COVID-19,” said Dr. Susana Cedres, a medical oncologist with Vall d’Hebron Hospital. “Malignant pleural mesothelioma patients are particularly vulnerable to COVID-19.” Cedres said since the subsequent rollout of the COVID-19 vaccines, no positive cases have been attributed to pleural mesothelioma patients at the hospital. The average age of the seven patients was 62. All had the epithelioid histology of mesothelioma and two were receiving oncologic treatment at the...
Source: Asbestos and Mesothelioma News - September 15, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

Norris Cotton Cancer Center Researchers Find Immune Cells That Guard Frequent Site of Cancer Spread
Researchers in the laboratory of Mary Jo Turk, PhD, Co-Director of the Immunology and Cancer Immunotherapy Research Program at Dartmouth’s and Dartmouth-Hitchcock’s Norris Cotton Cancer Center have spent the past year studying immunity to metastatic cancer within lymph nodes. (Source: News at Dartmouth Medical School)
Source: News at Dartmouth Medical School - September 14, 2021 Category: Hospital Management Authors: NonPerson Geisel Web Service Acct Tags: News Press Release Research Norris Cotton Cancer Center Source Type: news

I ’m Haunted by Sisters With Sickle Cell: Two Thrived. Two Suffered.
The cruelty of their unequal outcomes — with one pair freed of disabling symptoms and the other’s suffering unabated — stayed with me. (Source: NYT Health)
Source: NYT Health - September 14, 2021 Category: Consumer Health News Authors: Gina Kolata Tags: Genetics and Heredity Genetic Engineering Boston Children ' s Hospital Immunotherapy Clinical Trials Women and Girls Sickle Cell Anemia Stroke Tests (Medical) Transfusions Source Type: news

PET tracer predicts response to immunotherapy
An experimental PET radiotracer can predict whether patients will respond earl...Read more on AuntMinnie.comRelated Reading: PET identifies early responders to liver cancer treatment Second-look PET/CT catches cancer spread FDG-PET/CT aids in melanoma treatment assessment New PET tracer could aid melanoma detection MRI holds promise for immunotherapy but needs more research (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - September 14, 2021 Category: Radiology Source Type: news

SITC and AACR Outline Future Directions for Investigating...
The Society for Immunotherapy of Cancer (SITC) and the American Association for Cancer Research (AACR) have partnered to define recommendations for advancing the understanding of immune-related...(PRWeb September 14, 2021)Read the full story at https://www.prweb.com/releases/sitc_and_aacr_outline_future_directions_for_investigating_immune_related_adverse_events/prweb18194320.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - September 14, 2021 Category: Pharmaceuticals Source Type: news

Ramucirumab Shows Survival Benefits with Pleural Mesothelioma
Adding the drug ramucirumab to gemcitabine chemotherapy worked especially well in a recent clinical trial involving second-line treatment for patients with pleural mesothelioma. Ramucirumab, an immunotherapy drug also known by the brand name Cyramza, is a monoclonal antibody that works by targeting and restricting a protein that stimulates blood vessel growth within tumors. Impressive results in the phase II clinical trial moved the drug combination closer to filling the long-standing void for a second-line mesothelioma treatment. The Lancet Oncology recently published results of the study, which was conducted in ...
Source: Asbestos and Mesothelioma News - September 13, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

A 3-D Tumor Microenvironment for Personalized Immunotherapy
A new platform enables screening a wide range of combination anticancer therapeutics in a matter of days, which may translate to personalized therapeutic regimens for patients in less time. (Source: The Scientist)
Source: The Scientist - September 10, 2021 Category: Science Tags: Sponsored Article Source Type: news

How a cancer-fighting Peninsula biotech has sealed 3 collaborations and a big IPO this year
From the Stanford University lab of a cancer immunotherapy pioneer to an IPO, a small-but-growing Peninsula biotech company is looking to continue its win streak with its third biopharma collaboration of the year. Bolt Biotherapeutics Inc. of Redwood City said it will partner with drug giant Bristol-Myers Squibb Co. on a new combination of two of the companies' main drugs that could start a clinical trial yet this year. Bolt's (NASDAQ: BOLT) BDC-1001 will be combined with Bristol-Myers Squibb's… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - September 8, 2021 Category: Pharmaceuticals Authors: Ron Leuty Source Type: news

ATP Announces $40 Million in Series A Funding for srRNA Therapeutics Trailblazer Replicate Bioscience
NEW YORK and SAN DIEGO, Sept. 8, 2021 -- (Healthcare Sales & Marketing Network) -- ATP, a leader in life sciences venture capital, today announced the launch of Replicate Bioscience, a company pioneering ways to prevent drug resistance in cancer, and trea... Biopharmaceuticals, Venture Capital Replicate Bioscience, srRNA immunotherapies (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - September 8, 2021 Category: Pharmaceuticals Source Type: news

Mesothelioma Treatment Program Expanding in Central Florida
When he first joined AdventHealth Orlando in 2019, thoracic surgeon Dr. Marcelo DaSilva wondered just how successful he could be in creating a mesothelioma specialty center in Central Florida. Now he knows. DaSilva was initially hoping to create a program that would allow Florida mesothelioma patients to stay closer to home – instead of traveling across the country – and still get the best possible treatment for this rare, tough-to-treat malignancy. But he’s already done considerably more. His vision has grown, and so has his program. More patients will benefit greatly. DaSilva recently expand...
Source: Asbestos and Mesothelioma News - September 8, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

Characterization of new allergens from the venom of the European paper wasp Polistes dominula - Grosch J, Eberlein B, Waldherr S, Pascal M, San Bartolom é C, De La Roca Pinzón F, Dittmar M, Hilger C, Ollert M, Biedermann T, Darsow U, Bilò MB, Schmidt-Weber CB, Blank S.
Discriminating Polistes dominula and Vespula spp. venom allergy is of growing importance worldwide, as systemic reactions to either species' sting can lead to severe outcomes. Administering the correct allergen-specific immunotherapy is therefore a prerequ... (Source: SafetyLit)
Source: SafetyLit - September 4, 2021 Category: International Medicine & Public Health Tags: Non-Human Animals and Insects Source Type: news

On fast track to defeat cancer, Peninsula startup lands $108M from A-list investors
The company, launched in spring 2019 by veterans of Pfizer's now-shuttered cancer immunotherapy research center in South San Francisco, expects to grow to about 60 employees as it takes its first drug into its first clinical trial late next year. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - September 1, 2021 Category: Pharmaceuticals Authors: Ron Leuty Source Type: news

On fast track to defeat cancer, Peninsula startup lands $108M from A-list investors
The company, launched in spring 2019 by veterans of Pfizer's now-shuttered cancer immunotherapy research center in South San Francisco, expects to grow to about 60 employees as it takes its first drug into its first clinical trial late next year. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - September 1, 2021 Category: Biotechnology Authors: Ron Leuty Source Type: news

Accelerated Approval Now Full for Pembro in Bladder Cancer Accelerated Approval Now Full for Pembro in Bladder Cancer
A controversial accelerated approval of this immunotherapy, based on response data, has now been converted to a full approval by the FDA.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 1, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Targeted and Immunotherapies in BRAF Mutant Melanoma Targeted and Immunotherapies in BRAF Mutant Melanoma
Review the clinical considerations for choosing between MAPK inhibitors and immune checkpoint inhibitors as first-line therapy for BRAF mutant advanced melanoma.The British Journal of Dermatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 1, 2021 Category: Consumer Health News Tags: Dermatology Journal Article Source Type: news

Study: Pleural Mesothelioma Treatment Effective with Peritoneal Disease
We report the first real-world evidence regarding clinical outcomes for a cohort of patients with advanced MPeM receiving ICIs,” the MD Anderson study authors wrote. “Our results provide much-needed data supporting the role of ICIs in patients with this rare disease, who cannot participate in clinical trials and otherwise have no or limited treatment options.” The post Study: Pleural Mesothelioma Treatment Effective with Peritoneal Disease appeared first on Mesothelioma Center - Vital Services for Cancer Patients & Families. (Source: Asbestos and Mesothelioma News)
Source: Asbestos and Mesothelioma News - August 31, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

Researchers Study New Immunotherapy Combination for Mesothelioma
The immunotherapy combination of tremelimumab and durvalumab has shown surprising efficacy, particularly as a second-line treatment option for patients with pleural mesothelioma, according to a recent study. Its effectiveness, comparable to a similar combination which was approved in 2020 by the U.S. Food and Drug Administration, further illustrated the new direction for future treatment of mesothelioma. Chemotherapy will no longer be the stand-alone, standard-of-care treatment for most patients. “Promising results have emerged on the use of targeted treatment with immune checkpoint inhibitors (ICI), particu...
Source: Asbestos and Mesothelioma News - August 30, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

Mesothelioma Olaparib Clinical Trial Targets Genetic Mutation
The mesothelioma program at University of Chicago Medicine is recruiting patients for its latest clinical trial involving olaparib, an oral chemotherapy drug targeting cancer-driven genetic mutations. This single-center, phase II clinical trial is open to patients with either pleural mesothelioma or peritoneal mesothelioma. Olaparib, also known by the brand name Lynparza, works by repairing or controlling specific gene mutations. It is known as a protein inhibitor and has been approved by the U.S. Food and Drug Administration for use with breast and ovarian cancers. Mesothelioma, a rare malignancy caused by exposu...
Source: Asbestos and Mesothelioma News - August 24, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

Roche receives FDA approval for first companion diagnostic to identify dMMR solid tumour patients eligible for anti-PD-1 immunotherapy
Basel, 18 August 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced U.S. Food and Drug Administration (FDA) approval of the VENTANA MMR RxDx Panel, advancing the company's commitment to personalised healthcare through tests that determine which patients are most likely to benefit from specific and targeted therapies. The VENTANA MMR RxDx Panel is the first companion diagnostic test to aid in identifying patients whose solid tumours are deficient in DNA mismatch repair (MMR), who may be eligible for JEMPERLI (dostarlimab-gxly) monotherapy, an anti-PD-1 immunotherapy from GSK. The test evaluates a panel of MMR p...
Source: Roche Investor Update - August 18, 2021 Category: Pharmaceuticals Source Type: news

Roche receives FDA approval for first companion diagnostic to identify dMMR solid tumour patients eligible for anti-PD-1 immunotherapy
Basel, 18 August 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced U.S. Food and Drug Administration (FDA) approval of the VENTANA MMR RxDx Panel, advancing the company's commitment to personalised healthcare through tests that determine which patients are most likely to benefit from specific and targeted therapies. The VENTANA MMR RxDx Panel is the first companion diagnostic test to aid in identifying patients whose solid tumours are deficient in DNA mismatch repair (MMR), who may be eligible for JEMPERLI (dostarlimab-gxly) monotherapy, an anti-PD-1 immunotherapy from GSK. The test evaluates a panel of MMR p...
Source: Roche Media News - August 18, 2021 Category: Pharmaceuticals Source Type: news

Aspirin trialled as potential treatment for aggressive breast cancer
Hopes raised that drug could work well with immunotherapy for triple-negative breast cancer patientsAspirin is being trialled as part of a potential treatment for an aggressive form of breast cancer.Researchers hope the cheap and widely available drug could work well when combined with immunotherapy for patients with triple-negative breast cancer.Continue reading... (Source: Guardian Unlimited Science)
Source: Guardian Unlimited Science - August 18, 2021 Category: Science Authors: PA Media Tags: Breast cancer Aspirin Health Science Society Medical research UK news Source Type: news

Researchers launch clinical trial to see if aspirin could treat aggressive breast cancer
Researchers hope the cheap and widely available drug could work well when combined with immunotherapy for patients with triple negative breast cancer. (Source: the Mail online | Health)
Source: the Mail online | Health - August 18, 2021 Category: Consumer Health News Source Type: news

Palforzia Benefits for Peanut Allergy Continue Past First Year Palforzia Benefits for Peanut Allergy Continue Past First Year
Treating longer seems safer and more effective, but the field is still unsure about oral immunotherapy.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 16, 2021 Category: Consumer Health News Tags: Allergy & Clinical Immunology News Source Type: news

Chemotherapy-immunotherapy combination may work in lung cancer, study finds
A combination of two cancer treatments to target immune cells involved with the formation of lung tumors could provide an effective treatment for lung cancer, according to a study published Wednesday. (Source: Health News - UPI.com)
Source: Health News - UPI.com - August 11, 2021 Category: Consumer Health News Source Type: news

Immunotherapy May Help Fight Some Advanced Colon Cancers
A new report reveals immunotherapy helped extend the lives of some patients with the most common type of advanced colon cancer. (Source: WebMD Health)
Source: WebMD Health - August 11, 2021 Category: Consumer Health News Source Type: news

Immune-Based Therapy May Help Some Battling Advanced Colon Cancers
WEDNESDAY, Aug. 11, 2021 -- Immunotherapy helped extend the lives of some patients with the most common type of advanced colon cancer, researchers report. The new findings are important, they noted, because immunotherapy doesn't typically work... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - August 11, 2021 Category: General Medicine Source Type: news